1. Japan Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
KNC Laboratories Co.,Ltd.

KNC Laboratories Co.,Ltd.

6.70
EUR
+0.16
(+2.45%)
Nov 13Next Earn
KNC Laboratories Co.,Ltd.
FRA:7LW
(Frankfurt Stock Exchange)

Recent

price

6.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
624.94
794.67
1,039.52
814.86
820.51
777.46
957.23
1,118.79
1,186.46
1,058.45
1,175.21
- -
Revenue per Share
53
80.72
148.35
121.29
67.02
51.54
82.78
200.06
193.5
95.42
99.02
- -
Basic EPS, GAAP
-68.44
125.71
225.73
-89.16
-246.29
56.05
-31.94
112
110.18
-235.15
-46.98
- -
Free Cash Flow per Basic Share
2.71
10
14.82
24.92
24.93
24.96
24.95
35.22
32.97
30.97
32.97
- -
Dividend per Share
485.52
541.93
1,131.65
1,224.71
1,268.85
1,304.18
1,359.28
1,523.41
1,695.35
1,748.68
1,818.88
- -
Book Value per Share
457.57
536.9
1,127.9
1,214.54
1,258.07
1,296.36
1,353.41
1,515.17
1,688.43
1,742.02
1,811.01
- -
Tangible Book Value per Share
7
6
6
8
8
8
8
8
8
8
8
8
Basic Weighted Avg Shares
4,612
4,768
6,313
6,291
6,348
6,029
7,441
8,628
9,155
8,179
9,094
- -
Sales/Revenue/Turnover
6.45
14.87
19.36
19.72
9.05
10.54
14.71
25.08
22.74
9.44
11.27
- -
Operating Margin (%)
878
836
782
755
803
940
929
919
922
879
1,233
- -
Depreciation Expense
391
484
901
936
518
400
643
1,543
1,493
737
766
- -
Net Income, GAAP
- -
32.99
26.6
27.73
26.45
31.79
29.81
28.98
28.67
20.55
25.31
- -
Effective Tax Rate (%)
8.48
10.16
14.27
14.88
8.17
6.63
8.65
17.88
16.31
9.01
8.43
- -
Profit Margin (%)
610
890
4,151
2,442
2,619
3,850
4,301
4,731
5,590
5,207
5,085
- -
Working Capital
2,937
2,257
978
200
968
1,083
1,037
597
1,312
2,267
2,494
- -
LT Debt
3,748
4,184
8,737
9,455
9,827
10,121
10,575
11,745
13,087
13,520
14,081
- -
Total Equity
- -
6.16
9.39
8.08
3.82
3.74
6.29
11.56
9.78
3.67
4.41
- -
Return on Invested Capital (%)
- -
6.57
9.91
8.81
4.83
3.57
5.46
12.14
10.58
4.75
4.62
- -
Return on Capital (%)
- -
12.21
13.95
10.29
5.38
4.01
6.22
13.82
12.03
5.54
5.55
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
902
1,103
- -
LT Borrowings
2,278
2,494
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
- -
- -
9,187

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
7,191
7,811
- -
Cash, Cash Equivalents & STI
2,241
2,173
- -
Accounts Receivable, Net
1,071
1,735
- -
Inventories
3,344
3,291
- -
Total Current Liabilities
2,781
2,726
- -
Payables & Accruals
- -
- -
- -
ST Debt
902
1,103
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17%
6.88%
4.14%
Free Cash Flow
-126.41%
-200.06%
-79.99%
Net Income, GAAP
19.71%
30.17%
3.92%
Sales/Revenue/Turnover
7.73%
9.2%
11.18%
Total Cash Common Dividend
39.9%
6.93%
6.63%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
8,179
2026
- -
- -
- -
- -
9,094
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
95.42
2026
- -
- -
- -
- -
99.02
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
30.97
2026
- -
- -
- -
- -
32.97
2027
- -
- -
- -
- -
- -
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
KNC Laboratories Co., Ltd. KNC Laboratories Co., Ltd. (6568.T) engages in the research, development, and production of organic chemicals, providing contract manufacturing organization (CMO) and contract research organization (CRO) services across the pharmaceutical, electronic-chemical, agrochemical, energy, and environmental industries. The company offers core products and services including active pharmaceutical ingredients (APIs), protein and peptide synthesis, nucleic acid synthesis, bio-conversion processes, microbial culture, separation and purification technologies, scale-up and mass production of organic compounds, research reagents, original equipment manufacturing (OEM), full-time equivalent (FTE) research, sample production, period-defined custom research, and commercial production solutions. These capabilities support clients from early-stage research through to large-scale manufacturing, with specialized expertise in organic synthetic chemistry and biotechnology. Founded on January 22, 1985, and headquartered on Port Island in Chuo-ku, Kobe, Japan, KNC Laboratories operates primarily in Japan with facilities including the Kobe Plant, Kobe Laboratory, Izumo Plant, and historical sites such as the Iwaoka Plant and Ichikawa Laboratory. The company targets pharmaceutical companies, chemical manufacturers, and research institutions, delivering tailored solutions for drug development, reagent supply, and industrial applications. In recent developments, KNC Laboratories transitioned from the Tokyo Stock Exchange's Mothers market to the Growth market in April 2022, enhancing its visibility and access to capital markets. The company relocated its head office and Kobe Laboratory to Port Island, Chuo-ku, Kobe in December 2019, optimizing operations in a high-tech hub. As of April 1, 2025, it employs 346 staff and maintains a capital base of ¥1,995,106,630, with no major acquisitions, partnerships, or new product launches reported in the last 1-2 years.